National and international collaborations Zakaria Einbeigi, Khalil Helou, Erik Holmberg, Anikó Kovacs, Dan Lundstedt, Ella Ittner, Axel Stenmark-Tullberg, Toshima Parris, Mats Perman, Elisabeth Werner-Rönnerman, Fredrik Wärnberg, Anna Öfverholm, m.flįunders Swedish Cancer Society, Swedish Research Council, LUA-ALF Gothenburg, Jubileumsklinikens cancerfond, Swedish Radiation Safety Authority At an early stage we initiated a quality register, and monitoring of long-term outcomes is under way. The cancer genetic counseling clinic that has been in existence since the late 1990s has identified numerous BRCA carriers. We are now studying what characterizes increased sensitivity for induction of breast cancer. Studies of gene expression profiles and biomarkers that identify patients who are sensitive to radiation inductionWe have characterized a cohort of children who, long ago, received low doses of ionizing radiation treatment for benign cutaneous hemangioma. Research is also underway to understand the importance of the local immunological response for the radiation effect and how it can be modulated for optimal treatment impact. We are now working to develop a gene expression profile and biomarker that identify groups of patients with a “treatment omission profile” - that is, who do not need radiation treatment. We were able to identify a genomic profile for radiation resistance.īy studying the stromal area around the tumor, we have also been able to see that the tumor’s local immune response in terms of various measures, including the number of tumor-infiltrating lymphocytes, affects the local recurrence risk and the radiation treatment effect. From these patients, we extracted RNA from the tumors and analyzed mRNA expression. We carried out a randomized radiation treatment study, in which 1,178 patients with breast cancer who had undergone breast-preserving surgery were assigned randomly to receive radiation treatment or not. We have also started quality registers following up BRCA carriers in West Sweden.ĭevelopment of tumor and stromal gene expression profiles and biomarkers that identify whether breast cancer patient need radiation treatment or not.
In collaboration with the International Breast Cancer Study Group (IBCSG), we have also been the Swedish principal investigator (PI) for three major randomized trials (SOFT, TEXT, and SOLE) in which patients with hormone receptor-positive breast cancer were randomly assigned for various endocrine treatment options.We have published many articles based on our Swedish randomized studies in which patients with breast cancer who have undergone breast-preserving surgery were randomly assigned for radiation treatment or not.We were, for example, among those who developed Sweden’s national target and technical guidelines for radiation treatment of breast cancer. Over the years, we have conducted many clinical and translational studies in the area of breast cancer. Studies of gene expression profiles and biomarkers to identify patients who are sensitive to radiation induction īackground In research and clinical practice, the area of specialty is treatment of breast cancer.Development of tumor and stromal gene expression profiles and biomarkers that identify which breast cancer patients need radiation treatment and which do not.His research group - the Per Karlsson Group - has several national and international projects in progress. Per Karlsson holds a position as full Professor of Oncology at Sahlgrenska Academy, combined with a position as Senior Consultant in Oncology at Sahlgrenska University Hospital.